Moreover, PD-L2 positivity on combined tumor, stromal, and immune cells in HNSCC significantly predicted clinical response to anti-PD-1 pembrolizumab, independent of PD-L1 [42]. This evidence concerns the gene PDCD1 and neoplasm.